Key Drivers
- Strong Gross Margins
- Elevated Leverage
- Improved Cash Flow
AIAI Summary
TVTX is now a high-expectations FILSPARI commercial-execution story: sustained IgAN growth and a successful FSGS rollout could unlock powerful high-margin operating leverage, but its $5.3B valuation and heavy debt leave little room for slower adoption or continued cash-burn.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Gross Margins
- •Elevated Leverage
- •Improved Cash Flow
TVTX offers strong gross margins and liquidity, but recurring losses, sharply rising leverage, financing dependence, and an expensive valuation make it a high-risk investment pending sustained operational improvement.
Price Behavior
Key Price Behavior Insights:
- •Support retest
- •Resistance failures
- •Weak momentum
TVTX is weakening over the last month, with $62.50–$63.00 support critical; a break below it is bearish, while reclaiming $65.70 and $67.00 would signal improvement.
Sharp rebound to $64.74 after declines indicates active buyers
Sentiment & News
Key News Insights:
- •Institutional buying
- •FILSPARI growth
- •Buy valuation
Travere gains institutional backing and a bullish valuation as FILSPARI sales momentum supports upside potential despite HSBC's reduced stake.
Positive institutional interest and strong FILSPARI commercialization could support Travere's share-price outlook
Similar Companies in Healthcare
Other companies in the same sector with AI ratings